NDAORALTABLETPriority Review
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
TICLID (ticlopidine hydrochloride) by Roche is clinical pharmacology mechanism of action when taken orally, ticlopidine hydrochloride causes a time- and dose-dependent inhibition of both platelet aggregation and release of platelet granule constituents, as well as a prolongation of bleeding time. First approved in 1991.
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TICLID (ticlopidine hydrochloride) is an oral antiplatelet agent that irreversibly inhibits ADP-induced platelet aggregation and fibrinogen binding. It is used to reduce thrombotic stroke risk in patients with prior stroke or high-risk conditions. The drug works by interfering with platelet membrane function, producing effects that persist for the lifespan of the platelet.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); brand team size likely contracting as generics penetrate market.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action When taken orally, ticlopidine hydrochloride causes a time- and dose-dependent inhibition of both platelet aggregation and release of platelet granule constituents, as well as a prolongation of bleeding time. The intact drug has no significant activity at…
Worked on TICLID at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.